Rasagiline has 12 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbidopa, Carbidopa Tablets, Dextromethorphan. Patients taking Rasagiline should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 12
- Contraindicated
- 5
- Major
- 2
- Moderate
- 4
Contraindicated (5)
- Rasagiline + Carbidopa— Concomitant therapy may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone.
- Rasagiline + Carbidopa Tablets— Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.
- Rasagiline + Dextromethorphan— Contraindicated due to risk of psychosis or bizarre behavior with MAO inhibitors including selective MAO-B inhibitors.
- Rasagiline + Mao Inhibitors— Contraindicated due to increased risk of nonselective MAO inhibition that may lead to hypertensive crisis.
- Rasagiline + Meperidine— Serious, sometimes fatal reactions have been precipitated with concomitant use. Risk of serotonin syndrome.
Major (2)
- Rasagiline + Dopamine Hydrochloride— Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac ar…
- Rasagiline + Tetracycline— Concomitant use is not recommended due to risk of serotonin syndrome and hypertensive crisis.
Moderate (4)
- Rasagiline + Carbidopa And Levodopa— Selective MAO-B inhibitor may be associated with orthostatic hypotension when used concurrently; monitor patients.
- Rasagiline + Ciprofloxacin— CYP1A2 inhibitor that may increase rasagiline plasma concentrations up to 2-fold, resulting in increased adverse events.…
- Rasagiline + Droxidopa— Selective MAO-B inhibitor permitted in clinical trials but use with caution; monitor for increased blood pressure.
- Rasagiline + Foscarbidopa/Foslevodopa— Selective MAO-B inhibitor may cause orthostatic hypotension with VYALEV. Monitor patients taking these drugs.